RxDoctor Payments Data

Mildred Williams

Nurse Practitioner · Waxhaw, NCNPI 1548644826

Payments from drug & device makers

$1,893in general payments, 2019–2025

Across 110 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$384
  • AbbVie$234
  • Boehringer Ingelheim$185
  • Lilly USA, LLC$153
  • Novartis$145
  • Amgen$96
  • plus $696 from 19 others

What the payments were for

  • Food & beverage$1,893100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,893 in reported general payments places this provider in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$73,704
Medicare patients
205
Services billed
1,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$25,686
JardianceEmpagliflozin22$22,606
FarxigaDapagliflozin Propanediol13$15,745
MounjaroTirzepatide14$15,233
EliquisApixaban22$13,387
SynthroidLevothyroxine Sodium36$3,538
Rosuvastatin Calcium287$2,251
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,073
Levothyroxine Sodium167$1,677
Atorvastatin Calcium217$1,645
Gabapentin60$1,437
Omeprazole128$1,289
Losartan Potassium125$1,232
Amlodipine Besylate202$1,212
Albuterol Sulfate HfaAlbuterol Sulfate41$1,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$48$25,68623 claims
Boehringer IngelheimJardiance$185$22,60622 claims
AstraZenecaFarxiga$384$15,74513 claims
Lilly USA, LLCMounjaro$153$15,23314 claims
PfizerEliquis$20$13,38722 claims
AbbVieSynthroid$234$3,53836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Waxhaw

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →